IOVANCE BIOTHERAPEUTICS Files 8-K on Financials
Ticker: IOVA · Form: 8-K · Filed: May 8, 2025 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: IOVA
TL;DR
IOVA filed an 8-K on May 8, 2025, covering financial results and condition.
AI Summary
On May 8, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that Iovance Biotherapeutics is providing updates on its financial condition and results of operations, which is crucial for investors to assess the company's performance.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting financial condition and results of operations, without immediate news of significant events.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- May 8, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36860 (identifier) — Commission File Number
- 75-3254381 (identifier) — I.R.S. Employer Identification No.
- Lion Biotechnologies, Inc. (company) — Former Company Name
- Genesis Biopharma, Inc (company) — Former Company Name
- FREIGHT MANAGEMENT CORP (company) — Former Company Name
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the provided excerpt does not detail specific figures.
When was this 8-K report filed?
The report was filed on May 8, 2025.
What is the company's state of incorporation?
The company, IOVANCE BIOTHERAPEUTICS, INC., is incorporated in Delaware.
Has the company operated under any previous names?
Yes, the company was formerly known as Lion Biotechnologies, Inc., Genesis Biopharma, Inc, and FREIGHT MANAGEMENT CORP.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on the company's results of operations and financial condition, along with providing financial statements and exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding IOVANCE BIOTHERAPEUTICS, INC. (IOVA).